Anal cancer market 2017

Anal Cancer Market 2017: Industry Demand, Insight & Forecast By 2022 Anal Cancer Market Anal Cancer – Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer – Pipeline Review, H2 2017, provides an overview of the Anal Cancer (Oncology) pipeline landscape.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area. Predisposing factors include HPV infections, smoking and lowered immunity.

Browse Full Table of Contents and Report Description @ https://www.reportsmonitor.com/anal-cancer-pipeline-review-h2-2017/ Report Highlights Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Anal Cancer – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 10, 3 and 4 respectively.

Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries,

conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope – The pipeline guide provides a snapshot of the global therapeutic landscape of Anal Cancer (Oncology).

– The pipeline guide reviews pipeline therapeutics for Anal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Anal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Anal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Anal Cancer (Oncology) Reasons to buy – Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Anal Cancer (Oncology).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Anal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

For Requesting a Sample Copy of This Report, Please Visit @ https://goo.gl/5NjFXz Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Anal Cancer – Overview 6 Anal Cancer – Therapeutics Development 7 Pipeline Overview 7 Pipeline by Companies 8 Products under Development by Companies 10 Anal Cancer – Therapeutics Assessment 11 Assessment by Target 11 Assessment by Mechanism of Action 13 Assessment by Route of Administration 15 Assessment by Molecule Type 17 Anal Cancer – Companies Involved in Therapeutics Development 19 Advaxis Inc 19 Amgen Inc 19 Atara Biotherapeutics Inc 20 Bayer AG 20 BeiGene Ltd 21

Eli Lilly and Company 21 Immunovaccine Inc 22 ISA Pharmaceuticals BV 22 Merck & Co Inc 23 Ono Pharmaceutical Co Ltd 23 Oryx GmbH & Co KG 24 PDS Biotechnology Corp 24 Sun Pharma Advanced Research Company Ltd 25 Taiwan Liposome Company Ltd 25 Anal Cancer – Drug Profiles 26 ATA-368 – Drug Profile 26 axalimogene filolisbac – Drug Profile 27 axalimogene filolisbac second generation – Drug Profile 46 BAY-1125976 – Drug Profile 47 BGBA-317 – Drug Profile 48 cisplatin – Drug Profile 51 CUE-101 – Drug Profile 52 DPXE-7 – Drug Profile 53 ISA-101 – Drug Profile 55 nivolumab – Drug Profile 59 paclitaxel albumin free – Drug Profile 108 panitumumab – Drug Profile 109 PDS-0101 – Drug Profile 115 pembrolizumab – Drug Profile 117 prexasertib – Drug Profile 178 TLC-388 – Drug Profile 180 Vicoryx – Drug Profile 182 Anal Cancer – Dormant Projects 183 Anal Cancer – Discontinued Products 184 Anal Cancer – Product Development Milestones 185 Featured News & Press Releases 185 Appendix 196 Methodology 196 Coverage 196 Secondary Research 196

Primary Research 196 Expert Panel Validation 196 Contact Us 196 Disclaimer 197 About Us Reports Monitor (ReportsMonitor.com) is a platform to meet the market research and business intelligence requirements. Our aim is to change the dynamics of the Market Research industry by providing quality intelligence backed by data. Your requirement for market forecasting is fulfilled by our exclusive quantitative and analytics driven intelligence. We have a vast collection of reports, covering maximum industries worldwide. Our process is meticulously planned and executed in order to use maximum resources and explore the market for getting genuine insights. Decision makers can now rely on our distinct data gathering methods to get factual market forecasting and detailed analysis.

Contact Information: Jay Matthews Direct: +1 513 549-5911 Email: sales@reportsmonitor.com Website: www.reportsmonitor.com